Devyser Diagnostics AB (publ) (STO:DVYSR)

Market Cap	1.49B -10.8%
Revenue (ttm)	257.50M +16.5%
Net Income	15.00M
EPS	0.89
Shares Out	16.79M
PE Ratio	99.47
Forward PE	29.66
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,214
Open	90.00
Previous Close	89.00
Day's Range	87.40 - 90.00
52-Week Range	74.00 - 159.60
Beta	0.82
Analysts	Strong Buy
Price Target	153.17 (+72.88%)
Earnings Date	Jul 20, 2026

About Devyser Diagnostics AB

Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, hereditary cancer, and transfusion medicine products; and Amplicon Suite and Advyser for cloud-based software solutions for data analysis and the inter...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2004
• Employees: 110
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: DVYSR

Financial Performance

In 2025, Devyser Diagnostics AB's revenue was 250.50 million, an increase of 15.49% compared to the previous year's 216.90 million. Losses were -8.40 million, -86.34% less than in 2024.

Analyst Summary

According to 3 analysts, the average rating for DVYSR stock is "Strong Buy." The 12-month stock price target is kr 153.17, which is an increase of 72.88% from the latest price.

Price Target

kr 153.17

(72.88% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 16, 2026

Data Sources Report a data error